KUALA LUMPUR: While a patient group and an oncologist welcome the big price drop of trastuzumab, a breast cancer drug for HER2-positive patients, they urge the Health Ministry to remove the limiting criteria for selecting HER2+ patients to be treated.
Instead, they said HER2-positive patients should be given the choice to be treated regardless of age and cancer stage.
Already a subscriber? Log in.
Get 30% off with our ads free Premium Plan!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
